Biotech, Financing

Juno Therapeutics lands bumper $265 million IPO

Posted on 20 December 2014

Tags: ,

Juno Therapeutics announced the pricing of its initial public offering of 11,022,917 shares of common stock at a price to the public of $24.00 per share.

In addition, Juno Therapeutics has granted the underwriters a 30-day option to purchase up to an additional 1,653,437 shares of common stock to cover over-allotments, if any.

Searching for more deal information? Current Partnering offers the following options:

  • CP Reports | Browse titles | Over 200 report titles that focus upon different deal types from licensing, co-promotion to distribution, biomarkers to drug delivery, oncology to psychiatry, all of which provide you with an insight into the latest life science deal making trends
  • Current Agreements | Login | Find out more | Updated daily by our industry analysts, our fully searchable life sciences intelligence database allows you to find deals and alliances dating as far back as 2000 saving you valuable time on your deal making research activities

 

Juno Therapeutics’ common stock is expected to begin trading on The NASDAQ Global Select Market under the symbol “JUNO” on December 19, 2014.

The offering is expected to close on December 23, 2014, subject to customary closing conditions.

 

For further deal information visit Current Agreements (subscription required)

Related

Scorecard: Top partnering deals by value in 2014

View: Top pharmaceutical companies

View: Top biotech companies

Report: Top 50 Big Pharma Partnering and M&A Deal Trends

Report: Top 50 Big Biotech Partnering and M&A Deal Trends

Print Friendly, PDF & Email

Leave a Reply